游戏里的战斗激情,免费无码毛片一区二区A片小说 ,忍着娇喘人妻被中出中文字幕,中文字幕在线亚洲二区

北科生物Beike Biotechnology  
深圳市北科生物科技有限公司（簡稱北科生物），是中國專業(yè)從事干細(xì)胞基礎(chǔ)研究、臨床應(yīng)用研究及干細(xì)胞技術(shù)服務(wù)的生物高科技企業(yè)。在干細(xì)胞臨床應(yīng)用研究和技術(shù)服務(wù)等方面，北科生物始終和國際發(fā)展同步。北科生物對中國生物醫(yī)學(xué)技術(shù)的發(fā)展具有強(qiáng)烈的使命感，旨在通過對干細(xì)胞基礎(chǔ)研究和臨床應(yīng)用技術(shù)的持續(xù)、深入研究，使中國的生物醫(yī)學(xué)產(chǎn)業(yè)在國際競爭中占據(jù)一席之地。

北科生物自2005年7月成立以來，憑借著其在干細(xì)胞基礎(chǔ)研究和臨床應(yīng)用研究領(lǐng)域取得的積極成果，而備受國內(nèi)外關(guān)注和好評。北科生物是一家擁有自主知識產(chǎn)權(quán)的生物企業(yè)，目前已擁有8項(xiàng)重要的發(fā)明專利，1項(xiàng)實(shí)用新型專利，其中2項(xiàng)獲得授權(quán)。2006年9月深圳市科技和信息局授予北科生物為深圳市高新技術(shù)企業(yè)。

北科生物目前擁有員工約430名，其中56%以上為技術(shù)人員，擁有在干細(xì)胞研究領(lǐng)域成果卓越的多位院士及國內(nèi)外學(xué)者領(lǐng)銜的專業(yè)技術(shù)研發(fā)團(tuán)隊(duì)。

北科生物在海內(nèi)外投資成立了黑龍江省北科生物科技有限公司、遼寧北科生物科技有限公司、江蘇省北科生物科技有限公司、上海祥暉生物科技有限公司、湖北省北科生物科技有限公司、北科國際（香港）有限公司、Beike Biotech India Pvt. Ltd.（印度）和Beike-Siricell Holdings Inc.（泰國）。

北科生物一直孜孜不倦地在拓展新的產(chǎn)業(yè)發(fā)展思路，得到了政府各界的大力支持。江蘇北科即是借助政府各方面的支持，創(chuàng)建的一個嶄新的、具有突破性的技術(shù)平臺。江蘇北科下設(shè)中國醫(yī)藥城北科干細(xì)胞研究院，并獲得江蘇省科技廳批準(zhǔn)成立江蘇省干細(xì)胞與生物治療公共技術(shù)服務(wù)平臺（下設(shè)江蘇省干細(xì)胞庫、江蘇省生物治療研究中心），獲得江蘇省發(fā)改委批準(zhǔn)成立江蘇省干細(xì)胞與再生醫(yī)學(xué)工程中心，并且是江蘇省衛(wèi)生廳批準(zhǔn)的江蘇省干細(xì)胞與再生醫(yī)學(xué)基地的主要承建單位。同時，在2005年12月公司得到深圳市政府支持成立了深圳市北科細(xì)胞工程研究所，在2008年12月獲得深圳市科信局的立項(xiàng)支持成立了深圳市干細(xì)胞工程技術(shù)研究開發(fā)中心。

北科生物致力于干細(xì)胞技術(shù)從實(shí)驗(yàn)室到臨床應(yīng)用的一系列標(biāo)準(zhǔn)、規(guī)范和體系的建立和完善；致力于多種來源的成體干細(xì)胞的體外分離、培養(yǎng)、擴(kuò)增、誘導(dǎo)、分化及鑒定的基礎(chǔ)研究和臨床應(yīng)用研究；致力于多種干細(xì)胞組織工程產(chǎn)品的研究、開發(fā)，以及干細(xì)胞相關(guān)的藥物篩選平臺的建設(shè)；特別值得一提的是，在近兩年國內(nèi)外在干細(xì)胞領(lǐng)域取得突破性進(jìn)展的iPS技術(shù)領(lǐng)域，公司擁有自主知識產(chǎn)權(quán)并決定在該研究領(lǐng)域投入巨資。目前，北科生物已在全國各地建立了多個符合GMP標(biāo)準(zhǔn)的細(xì)胞實(shí)驗(yàn)室，已啟動ISO9001 質(zhì)量管理體系認(rèn)證，并積極參照AABB/FACT的相關(guān)標(biāo)準(zhǔn)，對公司現(xiàn)有質(zhì)控體系進(jìn)行完善和提高。

截至2009年，北科干細(xì)胞技術(shù)已經(jīng)治療病人6000多例，其中包括美國、加拿大、英國、匈牙利等40多個國家的500多名國外患者，獲得了顯著的治療效果。

北科生物已與清華大學(xué)深圳研究生院、香港中文大學(xué)、鄭州大學(xué)、匈牙利德布勒森大學(xué)及瑞典哥德堡大學(xué)等多所國內(nèi)外知名學(xué)府建立了科研合作關(guān)系。這種廣泛的國際、國內(nèi)科研合作，有利于發(fā)揮各自優(yōu)勢，確立我們在干細(xì)胞基礎(chǔ)研究和臨床科研領(lǐng)域的國際領(lǐng)先地位。

北科生物將本著“嚴(yán)謹(jǐn)、創(chuàng)新、關(guān)愛、服務(wù)”的企業(yè)理念，為干細(xì)胞技術(shù)能夠?yàn)槿祟惤】翟旄６恍缸非螅?br/>

Beike Biotechnology is a leading biotechnology company whose scientists have been dedicated to the development and commercialization of adult stem cell therapies since 1999. The company currently produces a full line of stem cell products derived from umbilical cord, cord blood, and bone marrow stem cells. Beike's proprietary processing and quality assurance technologies prepare the cells for use in treating a variety of serious medical conditions including ataxia, brain injury, cerebral palsy, diabetic foot disease, lower limb ischemia, multiple sclerosis, muscular dystrophy, spinal cord injury, and optic nerve damage.

Beike's stem cells are derived from healthy donors who are carefully screened for transmissible diseases. The samples are additionally screened by government appointed blood banks and Beike’s specialized laboratories. The stem cells are then banked in state-of-the-art facilities and only utilized in partnership with the best hospitals and physicians.

Stringent quality control procedures are undertaken at each of Beike‘s eighteen laboratories. Some of the laboratories are located inside the research departments of hospitals while others are located directly inside government blood banks. Beike also has two large stand alone laboratories where both research and stem cell processing take place. Beike, in partnership with the regional government, maintains a bank for the storage of stem cells located in the China Medical City in the Jiangsu province. This storage facility is capable of storing cord blood, cord mesenchymal, and iPS cells. All of the laboratories are outfitted with modern equipment and have been fully certified by the relevant drug authorities.

Treatment protocols include injections of umbilical cord blood stem cells, cord mesenchymal stem cells, and bone marrow mesenchymal stem cells directly into the spinal cord fluid and intravenously. However, for ailments like spinal cord injuries, liver disease, heart disease, muscular dystrophy, and lower limb ischemia, the stem cells are delivered through injections directly into the damaged tissue as well as through standard methods. For many diseases, protocols include rehabilitation and physical therapy.

Stem cells work by providing the body with paracrine and cytokines as well as a variety of other cell factors. These help to encourage the following functions:

1. Immune system regulation
2. Reducing cell death
3. Stimulation of growth of the patient’s own stem cells
4. Neo-angiogenesis (the growth of blood vessels resulting in increased blood flow to damaged areas)
5. Scar tissue reduction
6. Improving the effective conduction of intercellular electrical signals and transduction

Our research for future treatments is focused mainly on iPS technology in partnership with various leading scientific groups including Tsinghua Unversity. Beike’s scientists and partners have authored nearly eighty publications in Chinese scientific journals as well as ongoing clinical studies since our first ALS trial program in 2001. We very much welcome cooperation with international partners to help verify the effectiveness of our treatments and protocols and to license other technologies for use throughout our network of twenty seven hospitals。

The company was founded with capital from Beijing University, Hong Kong University of Science and Technology, and Shenzhen City Hall. The formation of the company was also supported with grants from the China State National Fund. Since that time, additional capital has been provided by a variety of Chinese venture capital firms.In total, Beike has received over US$6 million in Chinese government grants including a grant for a joint laboratory in Shenzhen with Tsingua University to focus on the study of stem cell reprogramming.

Beike‘s head office is located in Shenzhen but the company also has offices in Beijing, Nanjing, Taizhou, and Qingdao.

Stem Cell Processing Information

Umbilical Cord Blood (UCB) Stem Cells

For most ailments such as CP, ataxia, ALS, autism, and optic nerve hypoplasia, Beike's protocols utilize UCB stem cells. Our UCB stem cell doses consist of three subsets of stem cells. These are hematopoietic stem cells, endothelial progenitor cells, and mesenchymal stem cells. As has been shown in numerous studies, hematopoietic stem cells and endothelial progenitor stem cells are likely to form tissues in the body. Mesenchymal stem cells can assist in the growth of chondrocytes (a type of cell critical to tissue renewal, particularly cartilage), liver cells, kidney cells, and neurons, and also conduct repairs in relation to vascular disorders within the brain, ocular areas, and throughout the body including the heart, kidney, and pancreas.

Umbilical Cord Mesenchymal (UC-MSC) Stem Cells

Some of Beike's protocols, inclu